Dobbels Fabienne, Moons Philip, Abraham Ivo, Larsen Christian P, Dupont Lieven, De Geest Sabina
Center for Health Services and Nursing Research, Katholieke Universiteit Leuven, Leuven, Belgium.
Transpl Int. 2008 Aug;21(8):764-73. doi: 10.1111/j.1432-2277.2008.00674.x. Epub 2008 May 29.
Measurement of the patients' subjective experience of side-effects of immunosuppressants is a critical post-transplant outcome. This study aimed to update and validate the 45-item Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD) for novel immunosuppressive regimens. We used four steps: (1) literature review to identify immunosuppressant-related symptoms; (2) screening of adverse event forms; (3) international experts' evaluation of the appropriateness of each symptom; and (4) a pilot study in 24 renal transplant patients to test the clarity of instructions and items, and a pilot study in 84 lung transplant patients, to determine content and discriminant validity. Steps 1 and 2 produced a list of 76 symptoms. Clinical experts deemed 59 symptoms as being relevant for assessing symptom experience (step 3). Based on the first pilot testing, items and instructions were adapted to improve clarity. The second pilot testing showed that the updated MTSOSD-59R was easy to complete, that items and instructions were understandable, and that symptom profiles differed between males and females, and between depressed and nondepressed patients (step 4). The MTSOSD-59R is an instrument with established content and discriminant validity for assessing transplant patients' symptom experience of side-effects stemming from currently available immunosuppressive regimens.
测量患者对免疫抑制剂副作用的主观体验是移植后的一项关键结果。本研究旨在更新并验证用于新型免疫抑制方案的45项改良移植症状发生与症状困扰量表(MTSOSD)。我们采用了四个步骤:(1)文献综述以确定与免疫抑制剂相关的症状;(2)筛查不良事件表格;(3)国际专家对每种症状的适宜性进行评估;(4)对24例肾移植患者进行预试验以测试说明和条目是否清晰,对84例肺移植患者进行预试验以确定内容效度和区分效度。步骤1和步骤2产生了一份包含76种症状的清单。临床专家认为其中59种症状与评估症状体验相关(步骤3)。基于首次预试验,对条目和说明进行了调整以提高清晰度。第二次预试验表明,更新后的MTSOSD-59R易于完成,条目和说明易于理解,且男性与女性之间、抑郁患者与非抑郁患者之间的症状概况有所不同(步骤4)。MTSOSD-59R是一种具有既定内容效度和区分效度的工具,用于评估移植患者对当前可用免疫抑制方案副作用的症状体验。